An observational study in Joint Disease, sponsored by MicroPort Orthopedics Inc.. Enrolling by invitation at 1 site in Germany. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2023-11-14.
Sponsored by MicroPort Orthopedics Inc. (part of MicroPort Scientific Corporation) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Joint Diseases by MicroPort Scientific Corporation — 5 open to participants now, 13 under way, none of them phase 3. Joint Diseases · MicroPort Scientific Corporation.
Among the 21 studies in Joint Diseases by MicroPort Scientific Corporation, this one is the 5th largest by planned enrollment of the 20 observational ones that give a count, is one of 3 that started in 2019, is one of 20 observational ones, reaches primary completion later than 8 of the 12 other live ones, and was the 14th registered.
386 studies on the registry are indexed under Joint Diseases; 64 are open to participants now.
Browse Joint Diseases studies →5 of the 21 studies in Joint Diseases by MicroPort Scientific Corporation are open now, in 5 countries. Recruiting first, the newest first:
MicroPort Orthopedics Inc. · Sites in Italy
Ages 21+
MicroPort Orthopedics Inc. · Sites in United States, United Kingdom
Ages 21+
MicroPort Orthopedics Inc. · Sites in United States
Ages 21+
MicroPort Orthopedics Inc. · Sites in Poland
By country, each count listing its studies:
Of the 44 Joint Diseases studies recruiting now, 24 (55%) set no upper age limit and 11 (25%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 3 started in 2019.
This study's planned enrollment of 143 is above the median of 86 across 116 observational studies indexed under Joint Diseases.
Median enrollment 0 across the 1 interventional studies, 69 across the 20 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under MicroPort Orthopedics Inc., one of the names counted as MicroPort Scientific Corporation. Under that name alone:
MicroPort Orthopedics Inc. is the lead sponsor of 26 studies on the registry; 6 are open to participants now.
3 of the studies in Joint Diseases by MicroPort Scientific Corporation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02351414MicroPort Orthopedics Inc.Post Market Follow-Up Study of the EVOLUTION® Total Knee Arthroplasty System With Cruciate Sacrificing Inserts | 2027-06 |
| NCT02823834MicroPort Orthopedics Inc.PMCF Study Protocol for PROFEMUR® Gladiator Plasma Femoral Stems and PROCOTYL® L Beaded Acetabular Components | 2027-06 |
| NCT02239783MicroPort Orthopedics Inc.Post Market Clinical Follow-Up Study Protocol for PROFEMUR® TL Modular Femoral Stems | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies in Joint Diseases by MicroPort Scientific Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
MicroPort Orthopedics (MPO) is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) components marketed in the European Union (EU). These types of studies are required by regulatory authorities for all THA devices that do not have medium to long-term clinical evidence available at the time of gaining approval to market in Europe. This study has been designed in accordance with the medial device directives (MEDDEV) 2.12/2 rev 2.
Subjects previously implanted with any MicroPort Orthopedics or Wright Medical Technology Femoral Stems and PROCOTYL® C Acetabular Components
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be included in the study, subjects must meet all of the following criteria:
Previously implanted bilateral subjects can have both THAs (Total Hip Arthroscopy) enrolled in the study provided:
Exclusion Criteria:
Subjects will be excluded if they meet any of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single arm study of subjects previously implanted with any MicroPort Orthopedics or Wright Medical Technology femoral stems and PROCOTYL® C Acetabular Components
Device: PROCOTYL® C
Hip Arthroplasty
Also known as: Primary Total Hip Device
Component Survivorship
The primary endpoint is to evaluate component survivorship of the PROCOTYL® C Acetabular Components out to 10 years follow-up. Percentage of hips survived with no revision or replacement at 10-year.
Time frame: 10 years post-operative
To determine the cumulative incidence of component revision at specified intervals out to 10 years follow-up;
Percentage of hips that were revised or replaced at each of the intervals namely for Early (2-5 years), midterm (5-7 Year), and long-term (10-year) evaluation.
Time frame: 2-5 years, 5-7 years, and 10 years
To characterize functional scores, as assessed by Oxford Hip.
The study will be reporting the final Oxford Hip score, which is a summary over 12 items. Each of these items is 5-level Likert scale such as from 'not at all' to 'totally'.
Time frame: 2-5 years, 5-7 years, and 10 years
To characterize functional scores, as assessed by EQ-5D-3L scores.
EQ-5D-3L data will be summarized over 5 domains, namely, mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each domain has 3 levels: no problems, some problems, and extreme problems.
Time frame: 2-5 years, 5-7 years, and 10 years
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2019 (actual). Primary completion is estimated for Dec 2032, 165 months after the start.
Of 58 observational studies under Joint Diseases, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 153. This study's planned 165 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.